In an adult male with oligometastatic prostate cancer, when is it appropriate to stop or delay androgen deprivation therapy (ADT)?

Decision on Stopping or Delaying ADT in Oligometastatic Prostate Cancer

In oligometastatic prostate cancer, metastasis-directed therapy (MDT) with stereotactic body radiotherapy (SBRT) can delay or potentially avoid ADT initiation, particularly in patients with ≤3 metastatic lesions confirmed on PSMA PET/CT, though ADT remains the standard when combined therapy is not feasible.

Key Decision Framework

When to Delay ADT Initiation

For newly diagnosed oligometastatic disease (≤3 lesions):

• Consider MDT with SBRT as monotherapy to delay ADT start 1
• The EXTEND trial demonstrated median PFS of 47 months with MDT + continuous ADT versus 22 months with ADT alone 1
• SBRT alone can delay ADT initiation while maintaining disease control in carefully selected patients 2, 3
• This approach is most appropriate for patients with:
  • PSMA-RADS 4-5 lesions on PSMA PET/CT
  • Bone or non-regional lymph node metastases only
  • Good performance status and life expectancy >1 year

Critical caveat: The evidence strongly favors MDT + ADT combination over MDT alone for optimal outcomes. Using MDT to completely avoid ADT is investigational and should ideally occur within clinical trials 2, 4.

When to Stop ADT (Intermittent Approach)

For patients already on ADT with metastatic disease:

The decision between continuous versus intermittent ADT depends critically on disease burden and PSA response:

Intermittent ADT is reasonable for:

• Patients achieving PSA <4 ng/mL after 6 months of ADT 5
• Those with low metastatic burden (not high-volume disease per CHAARTED criteria) 6
• Patients prioritizing quality of life over marginal survival benefit 7, 5

However, continuous ADT remains preferred for:

• High-volume disease (visceral metastases or ≥4 bone lesions with ≥1 beyond vertebral bodies/pelvis) 6
• Patients with Gleason score >7 5
• Those with PSA nadir >0.2 ng/mL 8

The evidence is nuanced: The SWOG 9346 trial failed to demonstrate non-inferiority of intermittent ADT (median OS 5.1 vs 5.8 years), though quality of life measures favored intermittent therapy 7, 5. The 2-year risk of progression was significantly higher with intermittent ADT in patients with low PSA nadir (53% vs 31%) 8.

Practical Algorithm for Oligometastatic Disease

Step 1: Confirm oligometastatic status

• Use PSMA PET/CT imaging (preferred over conventional imaging) 9
• Define as ≤3 metastatic lesions 2, 4
• Assess metastatic burden using CHAARTED criteria 6

Step 2: Risk stratification

• Low burden + PSA doubling time >12 months: Consider observation or MDT alone 10, 11
• Low burden + PSA doubling time <12 months: MDT + time-limited ADT 4
• High burden disease: Immediate ADT + MDT + consider ARPI 6, 9

Step 3: If initiating ADT, determine duration

• For patients receiving MDT: Consider time-limited ADT (duration based on risk factors) 4
• Monitor PSA and testosterone closely during any off-treatment periods 5, 11
• Switch to continuous ADT if PSA rises rapidly or symptoms develop 11

Critical Monitoring Parameters

During ADT holidays (intermittent approach):

• PSA monitoring every 3 months 5
• Testosterone level assessment 5
• Restart ADT when PSA reaches 10-20 ng/mL (trial-dependent thresholds) 5
• Be aware that testosterone may remain at castrate levels for 4 months after stopping ADT 8

Important pitfall: Testosterone recovery is incomplete in many patients—92% normalize after first cycle but only 46% after second cycle 8. This may explain why quality of life benefits of intermittent ADT are less pronounced than expected.

Contraindications to Delaying/Stopping ADT

Never delay ADT in:

• Symptomatic metastatic disease (Category 1 recommendation) 10
• Impending spinal cord compression 10
• High-volume metastatic disease without MDT 6
• Rapidly rising PSA (>50 ng/mL or doubling time <3 months) with long life expectancy 10

Quality of Life Considerations

While intermittent ADT shows modest improvements in erectile function, libido, and mental health after 3 months off treatment 5, 11, these benefits must be weighed against the potential 14-month survival disadvantage in high-risk patients (Gleason >7) 5. The cumulative side effects of continuous ADT—including osteoporosis, cardiovascular disease, metabolic syndrome—increase with duration 5, 10, making the intermittent approach attractive for carefully selected patients.

The modern paradigm is shifting: With emerging data showing MDT + ADT improves PFS compared to ADT alone (HR 0.50) 1, the focus should be on combining local and systemic therapies rather than simply choosing between them. For oligometastatic patients, the question is not whether to delay ADT indefinitely, but rather how to optimally integrate MDT to minimize ADT exposure while maximizing disease control.